| Pair Name | Curcumin, Carfilzomib | ||
| Phytochemical Name | Curcumin (PubChem CID: 969516 ) | ||
| Anticancer drug Name | Carfilzomib (PubChem CID: 11556711 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Curcumin, Carfilzomib | |||
| Disease Info | [ICD-11: 2A83.1] | Plasma cell myeloma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | CDH13 | hsa1012 |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Down-regulation | Phosphorylation | NFKBIA | hsa4792 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 |
| Result | Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination | |||
| No. | Title | Href |
|---|---|---|
| 1 | Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Toxicol In Vitro. 2018 Mar;47:186-194. doi: 10.1016/j.tiv.2017.12.001. | Click |
